Sep 26, 2023 / 06:00PM GMT
Dev Prasad Jefferies LLC-Analyst
[Good afternoon] everyone. My name is Dev Prasad. I'm an associate on our Senior Analyst Kelly Shi's team here at Jefferies, and thank you for attending our Cell and Gene Medicine Summit in New York. We are very pleased to have Dr. Mark Frattini, CMO from Cellectis, joining us today to share insight on Cellectis. Welcome.
Mark Frattini Cellectis S.A.-Chief Medical Officer
Hi there. Nice to be here. Thank you.
Questions and Answers:
Dev Prasad Jefferies LLC-AnalystMaybe we can start off with one of the more important debate going on in the industry, which is autologous versus allogeneic CAR-T approaches. And if you can provide the opportunity for alloCART and continue the discussion. And what's the differentiation of TALEN gene editing platform versus the others that are working to bring allogeneic CAR-T to market?
Mark Frattini Cellectis S.A.-Chief Medical Officer
Sure. Thanks for the question. So in